Immunosuppressant and steroid therapy for SLE have not shown satisfactory results. Another method of therapy that is being developed is vaccines and escalating dose immunotherapy using self-antigen.
about five million people. In Indonesia, the trend of lupus disease in hospitalized patients has increased since 2014 -2016 (Pusdatin Kemenkes, 2017 . SLE is characterized by a loss of globally immune tolerance with activation of autoreactive T cells and B cells that lead to the production of pathogenic autoantibodies and tissue damage (Choi et al., 2012) . The presence of abnormalities of the immune system is Therefore, it is still necessary to develop SLE therapy in inducing and improving the regulation of the immune system against autoantigen so as to improve the clinical condition of SLE patient's maximally (Handono et al., 2013) .
A recent study has found a method of immunological therapy in allergic and autoimmune diseases, namely Escalating Dose (Antigen-Specific) Immunotherapy (EDI). EDI is a therapeutic method for suppressing the immune response through a tolerance mechanism by injecting an autoantigen (selfantigen) that stimulates the formation of autoantibodies with a gradual dose to elicit a desensitization effect. Gradual and increased dosing is done to avoid adverse effects from the mild to the most severe, anaphylactic shock (Larché and Wraith, 2005) .
T-reg cells have an important role in the development of tolerance therapy with specific antigen. Induction of IL10 cytokines as immunomodulatory demonstrates the effectiveness of immunotherapy in both mice and humans (Tarzi et al., 2006; Campbell et al., 2009; Fousteri et al., 2010 et al., 2010; Dolff et al., 2011; Guimaraes et al., 2017) 
METHODS

Mice
Female Balb/c mice that were 6-8-weeks-old and 20-30 grams body weight were obtained from Veterinarian Center (Malang, Indonesia).
All mice were housed at Pharmacology Laboratory, Faculty of Medicine Universitas Brawijaya, given for water and food ad libitum.
Isolation dsDNA and Preparation
The ds-DNA antigen was isolated from the blood of healthy mice. 
Cell preparation
Preparation from spleen tissue was done using previous protocol methods. Spleen tissues were harvested and teased apart into suspension by pressing them with the plunger. Tissues were collected in 10 ml of staining buffer and passed cell suspension through a cell strainer to eliminate clumps and debris, then collected cell suspension in a conical tube. The cell suspension was centrifuged for 4-5 min (300-400x g) at 4°C and the supernatant was removed. Red blood cell lysis was performed.
Samples were resuspended in 50 ml of staining buffer.
Flowcytometry analysis
Cells that had been taken from spleen were stained using antibody markers to assess CD4+ Active dendritic cells were stained using antimouse CD45-PE and CD11b-FITC which has been diluted with CSB with a certain ratio.
Inactive dendritic cells were stained using anti- 
